Literature DB >> 19149594

Advances in peptide pharmaceuticals.

Cynthia L Stevenson1.   

Abstract

Drug delivery strategies for peptide pharmaceuticals have incorporated a wide range of structure activity relationships, analog generation to impart protease resistance and increased bioavailability, novel formulations, and delivery systems to target optimal therapeutic dosing requirements. Advances in peptide pharmaceuticals have provided products for the treatment of diabetes, obesity, Crohn's disease, osteoporosis, cancer, cardiovascular disease, immunotherapy, acromegaly, enuresis, pain, and antimicrobials. Here we review these marketed peptides and new peptidomimetic therapies currently in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19149594     DOI: 10.2174/138920109787048634

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  21 in total

1.  On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications.

Authors:  Frédéric Couture; François D'Anjou; Robert Day
Journal:  Biomol Concepts       Date:  2011-10-01

2.  The SCHOOL of nature: III. From mechanistic understanding to novel therapies.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-06-11

3.  Investigations into the fate of inhaled salmon calcitonin at the respiratory epithelial barrier.

Authors:  Leonie Baginski; Frederic Tewes; Stephen T Buckley; Anne Marie Healy; Udo Bakowsky; Carsten Ehrhardt
Journal:  Pharm Res       Date:  2011-08-05       Impact factor: 4.200

Review 4.  Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals?

Authors:  Nicole K Brogden; Kim A Brogden
Journal:  Int J Antimicrob Agents       Date:  2011-07-05       Impact factor: 5.283

5.  The pentapeptide PLNPK inhibits systemic lupus erythematosus-associated renal damage.

Authors:  Jun-qiang Lv; Wen Zhang; Song Wang; Lin Zhao; Rui Ma; Jin-wei Hu; Li-juan Wang; Jie Meng; Chun-lei Zhou; Gang Lin; Rong Lu; Zhi Yao
Journal:  Inflamm Res       Date:  2010-07-01       Impact factor: 4.575

Review 6.  Advances in Development of Antimicrobial Peptidomimetics as Potential Drugs.

Authors:  Natalia Molchanova; Paul R Hansen; Henrik Franzyk
Journal:  Molecules       Date:  2017-08-29       Impact factor: 4.411

Review 7.  Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides.

Authors:  Polina Feldman; Rajesh Khanna
Journal:  Neurosci Lett       Date:  2013-07-03       Impact factor: 3.046

Review 8.  Anti-angiogenic peptides for cancer therapeutics.

Authors:  Elena V Rosca; Jacob E Koskimaki; Corban G Rivera; Niranjan B Pandey; Amir P Tamiz; Aleksander S Popel
Journal:  Curr Pharm Biotechnol       Date:  2011-08       Impact factor: 2.837

Review 9.  Protease-resistant peptide design-empowering nature's fragile warriors against HIV.

Authors:  Matthew T Weinstock; J Nicholas Francis; Joseph S Redman; Michael S Kay
Journal:  Biopolymers       Date:  2012       Impact factor: 2.505

Review 10.  Strategies for identifying synthetic peptides to act as inhibitors of NADPH oxidases, or "all that you did and did not want to know about Nox inhibitory peptides".

Authors:  Iris Dahan; Edgar Pick
Journal:  Cell Mol Life Sci       Date:  2012-05-06       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.